Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,650 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,128 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,492)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00064350 | Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer | completed | Phase 2 | 342 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00080938 | Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer | completed | Phase 2 | 26 | Eastern Cooperative Oncology GroupNETWORK | 0 | Jun 29, 2023 | clinicaltrials |
| NCT01824901 | Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 2 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00103207 | Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer | completed | Phase 2 | 72 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 28, 2023 | clinicaltrials |
| NCT01104155 | Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 123 | Eisai Inc.INDUSTRY | 7 | Jun 22, 2023 | clinicaltrials |
| NCT01126736 | Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 98 | Eisai Inc.INDUSTRY | 5 | Jun 22, 2023 | clinicaltrials |
| NCT00006004 | Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 4 | Jun 15, 2023 | clinicaltrials |
| NCT00041314 | Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 4 | Jun 15, 2023 | clinicaltrials |
| NCT03345810 | Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)(DURATION) | completed | Phase 2 | 200 | AIO-Studien-gGmbHOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT03743129 | Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029）(ALTER-L029) | completed | Phase 2 | 90 | Anhui Shi, MDOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT03373760 | Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer | completed | Phase 2 | 67 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 9, 2023 | clinicaltrials |
| NCT02666105 | Exemestane in Post-Menopausal Women With NSCLC | completed | Phase 2 | 6 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT01004731 | Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer | completed | Phase 1 / Phase 2 | 7 | University of Alabama at BirminghamOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT02766335 | Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers | completed | Phase 2 / Phase 3 | 116 | SWOG Cancer Research NetworkNETWORK | 1 | May 25, 2023 | clinicaltrials |
| NCT04507217 | Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC | completed | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT03102242 | Atezolizumab Immunotherapy in Patients With Advanced NSCLC | completed | Phase 2 | 64 | Alliance Foundation Trials, LLC.OTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT02045446 | Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial | completed | Phase 2 | 29 | University of Texas Southwestern Medical CenterOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT03304093 | Immunotherapy by Nivolumab for HIV+ Patients(CHIVA2) | completed | Phase 2 | 30 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT00301808 | Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer | completed | Phase 2 | 29 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT03455829 | G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 30 | G1 Therapeutics, Inc.INDUSTRY | 1 | May 6, 2023 | clinicaltrials |
| NCT02659059 | Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer(CheckMate 568) | completed | Phase 2 | 324 | Bristol-Myers SquibbINDUSTRY | 2 | Apr 5, 2023 | clinicaltrials |
| NCT03406468 | Re-Induction After Initial Response With Immune Therapy With Radiotherapy in Lung Cancer | completed | Phase 2 | 36 | Maastricht Radiation OncologyOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05792995 | Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T Lymphocytes | completed | Phase 2 | 80 | Xin-Hua XuOTHER | 1 | Mar 31, 2023 | clinicaltrials |
| NCT02872701 | OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules | completed | Phase 2 | 100 | On Target Laboratories, LLCINDUSTRY | 2 | Mar 24, 2023 | clinicaltrials |
| NCT00385606 | Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLC | completed | Phase 2 / Phase 3 | 400 | National Cancer Institute, NaplesOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT01296113 | Chemotherapy for Lung Cancer in HIV-positive Patients(CHIVA) | completed | Phase 2 | 61 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
| NCT03825510 | Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect(I-SABR) | completed | Phase 2 | 3 | Crozer-Keystone Health SystemOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT03904563 | Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma | completed | Phase 2 | 27 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT02151604 | Hyperpolarized Xenon Gas MR Imaging in NSCLC Radiotherapy | completed | Phase 2 | 22 | Oxford University Hospitals NHS TrustOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT02713529 | Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer | completed | Phase 1 / Phase 2 | 117 | AmMax Bio, Inc.INDUSTRY | 6 | Jan 20, 2023 | clinicaltrials |
| NCT03693547 | Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer（NSCLC） | completed | Phase 2 | 26 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 10, 2023 | clinicaltrials |
| NCT00312728 | A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT) | completed | Phase 2 | 115 | Genentech, Inc.INDUSTRY | 0 | Jan 6, 2023 | clinicaltrials |
| NCT02591615 | Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC | completed | Phase 2 | 91 | Alliance Foundation Trials, LLC.OTHER | 1 | Dec 28, 2022 | clinicaltrials |
| NCT04201756 | Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma | completed | Phase 2 | 47 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT04444427 | Evaluation of GLR2007 for Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 19 | Gan and Lee Pharmaceuticals, USAINDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT01177397 | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | completed | Phase 1 / Phase 2 | 226 | CelgeneINDUSTRY | 4 | Dec 13, 2022 | clinicaltrials |
| NCT03853187 | Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer(Donan) | completed | Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT03090737 | Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer(CheckMate 907) | completed | Phase 2 | 129 | Bristol-Myers SquibbINDUSTRY | 5 | Dec 5, 2022 | clinicaltrials |
| NCT03360929 | Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759 | completed | Phase 1 / Phase 2 | 15 | LYZZ Alpha Holding LtdINDUSTRY | 1 | Nov 25, 2022 | clinicaltrials |
| NCT01649947 | Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II | completed | Phase 2 | 32 | Rutgers, The State University of New JerseyOTHER | 1 | Nov 21, 2022 | clinicaltrials |
| NCT02409368 | An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC(Checkmate 171) | completed | Phase 2 | 812 | Bristol-Myers SquibbINDUSTRY | 13 | Nov 14, 2022 | clinicaltrials |
| NCT01982955 | Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) | completed | Phase 1 / Phase 2 | 88 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 7 | Nov 8, 2022 | clinicaltrials |
| NCT02039674 | A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) | completed | Phase 1 / Phase 2 | 267 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 8, 2022 | clinicaltrials |
| NCT03900117 | Hypofractionated Radiotherapy Followed by Hypo-boost for Local Advanced NSCLC | completed | Phase 2 | 77 | Sun Yat-sen UniversityOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT02448225 | 18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules | completed | Phase 2 | 46 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT02359019 | MK-3475 as Maintenance Therapy in Extensive Stage SCLC | completed | Phase 2 | 45 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT02898116 | Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 2 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT03164772 | Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC | completed | Phase 1 / Phase 2 | 61 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT02293005 | Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma | completed | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 4, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jun 29, 2023source: clinicaltrials